Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
When in doubt about solution age or condition, reconstitute fresh
Source List Peer-Reviewed & Established Academic Sources Only PMC / NIH Pickart L
Presented for research literature review only Provost E et al
FOXO4-DRI is among the highest-risk research peptides from an evidence-to-risk standpoint: it has never been tested in humans, no human pharmacokinetic data exists, and as a senolytic it carries theoretical risks specific to its mechanism
Key publications: 'Tripeptide in human serum which prolongs survival of normal liver cells' (1973), 'Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells' (1980, Nature), 'The human tri-peptide GHK and tissue remodeling' (2008), 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration' (2015), 'Regenerative and Protective Actions of the GHK-Cu Peptide' (2018)
US$ 20.51
US$ 29.21
US$ 28.26
US$ 20.89
US$ 21.45
US$ 22.35
US$ 28.18
US$ 20.51
US$ 29.28
